OVERVIEW
This interactive and dynamic 60-minute symposium will review the standard of care and recommendations for early and aggressive treatment of chronic kidney disease (CKD) and will discuss the role of novel therapies that may optimize treatment of CKD. Two thought-provoking patient cases at different stages of the disease will be discussed. The audience will be called upon to answer live polling questions on how they would approach the management of these patients. The expert faculty will then discuss best clinical practices for improving the care and the outcomes for these patients.
IMPORTANT INFO
This symposium will be offered both in person and virtually. Please note: you will need to be a registered attendee of ERA 2024 in order to participate.
GOAL STATEMENT
The goal of this activity is for learners to be better able to discuss the recommendations for early and aggressive treatment of chronic kidney disease (CKD) and the role of novel therapies that may optimize treatment of CKD, and to use disease modifying therapies to slow CKD progression.
LEARNING OBJECTIVES
Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST][ITEM]Standard of care recommendations for early and aggressive CKD management [ITEM]Novel therapies that may optimize treatment of CKD[/LIST]Have greater competence related to [LIST][ITEM]Using disease modifying therapies to slow CKD progression[/LIST]Demonstrate greater confidence in their ability to [LIST][ITEM]Implement transformative changes to improve patient care and outcomes [/LIST]
Stockholmsmässan
Room: A4
Mässvägen 1 Älvsjö
Stockholm, Sweden, 125 80
Held at ERA 2024
Supported by an independent educational grant from [bold]AstraZeneca[/bold].